Page 11 - Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo.

SocietyBreast cancer, a pervasive global health concern, is increasingly making its presence felt among young women in the subcontinent. While traditionally perceived as a disease affecting older age groups, recent trends point to a disturbing rise...

Informed consent represents one of the most important ethical aspects of clinical treatments and scientific research involving humans.

A breakthrough new drug to treat brain disease is always welcome news. Last summer, the performance of the drugs donanemab and lecanemab in clinical trials...

New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE